Literature DB >> 19729975

Effect of low-dose Paclitaxel and docetaxel on endothelial progenitor cells.

Mariko Muta1, Tomonori Yanagawa, Yoshimichi Sai, Shigehira Saji, Eiji Suzuki, Tomoyuki Aruga, Katsumasa Kuroi, Gaku Matsumoto, Masakazu Toi, Emi Nakashima.   

Abstract

OBJECTIVE: Bone marrow (BM)-derived endothelial progenitor cells (EPC) play an important role in neovascularization and tumor growth. It has been reported that docetaxel and paclitaxel inhibit angiogenesis, but the effect of docetaxel and paclitaxel on EPC-induced neovascularization has not been examined. We aimed to clarify the cytotoxic and inhibitory effects of these drugs on EPC.
METHODS: The effects of drugs on growth, tube formation, and migration of EPC were analyzed in vitro using a rat BM-derived EPC cell line (TR-BME). Fluorescence-labeled TR-BME cells were injected into tumor-bearing rats and accumulation at the tumor site was analyzed by fluorescence-activated cell sorting (FACS).
RESULTS: In in vitro cytotoxicity assays of these drugs in TR-BME, rat endothelial cell line TR-BBB and rat tumor cell line Walker 256, the IC(50) values for TR-BME were higher than those for TR-BBB or Walker 256. Both drugs inhibited tube formation and migration of TR-BME at lower concentrations than the cytotoxic IC(50). In vivo studies showed that a low dose of both drugs inhibited EPC accumulation at the tumor site in tumor-bearing rats, as determined by FACS, and caused a decrease in microvessel density.
CONCLUSION: Docetaxel and paclitaxel directly inhibited EPC-initiated vasculogenesis at low (non-cytotoxic) concentrations, causing suppression of tumor growth. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729975     DOI: 10.1159/000236016

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  5 in total

Review 1.  Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer.

Authors:  Justin Q Wang; Austin DeChalus; Devin N Chatterjee; Evan T Keller; Atsushi Mizokami; Giovanni Camussi; Andrew R Mendelsohn; Joseph F Renzulli Ii; Peter J Quesenberry; Devasis Chatterjee
Journal:  Crit Rev Oncog       Date:  2015

Review 2.  Bevacizumab and breast cancer: current therapeutic progress and future perspectives.

Authors:  Sherry X Yang
Journal:  Expert Rev Anticancer Ther       Date:  2009-12       Impact factor: 4.512

3.  Biomimetic microfluidic platform for the quantification of transient endothelial monolayer permeability and therapeutic transport under mimicked cancerous conditions.

Authors:  Christopher George Uhl; Vladimir R Muzykantov; Yaling Liu
Journal:  Biomicrofluidics       Date:  2018-01-02       Impact factor: 2.800

4.  Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.

Authors:  Daisuke Sano; David R Fooshee; Mei Zhao; Genevieve A Andrews; Mitchell J Frederick; Chad Galer; Zvonimir L Milas; Phuong Khanh H Morrow; Jeffrey N Myers
Journal:  Head Neck       Date:  2011-03       Impact factor: 3.147

Review 5.  The pharmacological bases of the antiangiogenic activity of paclitaxel.

Authors:  Guido Bocci; Antonello Di Paolo; Romano Danesi
Journal:  Angiogenesis       Date:  2013-02-07       Impact factor: 9.596

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.